Clinical research in epithelial ovarian cancer and patients' outcome

Annals of Oncology

Volumn 22, Issue SUPPL.7, 2011, Pages 16-19

  Rochon, J ^a   Du Bois, A ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b KLINIKEN ESSEN MITTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL RESEARCH; CYTOREDUCTIVE SURGERY; FEMALE; FOLLOW UP; GERMANY; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PATIENT PARTICIPATION; PRIORITY JOURNAL; SURVIVAL TIME; CLINICAL TRIAL (TOPIC); HEALTH CARE DELIVERY; MEDICAL RESEARCH; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; NEOPLASM; OVARY TUMOR; PATHOLOGY; PRACTICE GUIDELINE; PROPORTIONAL HAZARDS MODEL; STANDARD; TREATMENT OUTCOME;

AGED; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DELIVERY OF HEALTH CARE; FEMALE; GUIDELINE ADHERENCE; HUMANS; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME;

EID: 84855439080     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr421     Document Type: Article

References (10)

1. Du Bois A, Rochon J, Lamparter C, Pfisterer J. Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer. Int J Gynecol Cancer 2005; 15: 183-191.
2. Du Bois A, Rochon J, Pfisterer J, Hoskins WJ. Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. Gynecol Oncol 2009; 112(2): 422-436.
3. Robinson WR, Ritter J, Rogers AS et al. Clinical trial participation is associated with improved outcome in women with ovarian cancer. Int J Gynecol Cancer 2009; 19: 124-128.
4. Karjalainen S, Palva I. Do treatment protocols improve end results? A study of survival of patients with multiple myeloma in Finland. Br Med J 1989; 299: 1069-1072.
5. Davis S, Wright PW, Schulman SF et al. Participants in prospective, randomized clinical trials for resected non-small cell lung cancer have improved survival compared with nonparticipants in such trials. Cancer 1985; 56: 1710-1708.
6. Braunholtz DA, Edwards SJ, Lilford RJ. Are randomized clinical trials good for us (in the short term)? Evidence for a 'trial effect'. J Clin Epidemiol 2001; 54(3): 217-224.
7. ECRI Evidence Report. Patients' reasons for participation in clinical trials and effect of trial participation on patient outcomes. ECRI Health Technology Assessment Information Service 2002; Vol. 74: Available at: https://www.ecri.org/Documents/Clinical_Trials_Patient_Guide_Evidence_Report.pdf.
8. Peppercorn JM, Weeks JC, Cook EF, Joffe S. Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet 2004; 363(9405): 263-270.
9. Vist GE, Bryant D, Somerville L et al. Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate. Cochrane Database Syst Rev 2008 (3): MR000009.
10. Pfisterer J, Weber B, Reuss A et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: A gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst 2006; 98(15): 1036-1045.